ArticleJournal of the American College of Cardiology2001
Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation.
Article in Journal of the American College of Cardiology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03007524 (A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome
Who cites it
10 citing papers in PubMed, 118 citations in OpenAlex.
- The effects of prior beta-blocker therapy on serum C-reactive protein levels after percutaneous coronary intervention.Clinical cardiology · 2005Trial
- Lipid-lowering medication reduces more target lesion than non-target lesion revascularizations: a cohort study.Annals of medicine · 2026Article
- Adventitial delivery of nanoparticles encapsulated with 1α, 25-dihydroxyvitamin DScientific reports · 2021Article
- The Preoperative Inflammatory Status Affects the Clinical Outcome in Cardiac Surgery.Antibiotics (Basel, Switzerland) · 2019Article
- Early Statins after Intravenous or Endovascular Recanalization Is Beneficial Regardless of Timing, Intensity, and Stroke Mechanism.Journal of stroke · 2017Article
- Vitamin D and acute myocardial infarction.World journal of cardiology · 2017Review
- Effect of statins and white blood cell count on mortality in patients with ischemic left ventricular dysfunction undergoing percutaneous coronary intervention.Clinical cardiology · 2006Article
- Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease.Heart (British Cardiac Society) · 2005Article
- C-reactive protein plasma levels but not factor VII activity predict clinical outcome in patients undergoing elective coronary intervention.Clinical cardiology · 2004Article
- HbA1c in Patients with Polycystic Ovary Syndrome: A Potential Marker of Inflammation.Journal of reproduction & infertilityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe sought to investigate whether statin therapy affects the association between preprocedural C-reactive protein (CRP) levels and the risk for recurrent coronary events in patients undergoing coronary stent implantation.
backgroundLow-grade inflammation as detected by elevated CRP levels predicts the risk of recurrent coronary events. The effect of inflammation on coronary risk may be attenuated by statin therapy.
methodsWe investigated a potential interrelation among statin therapy, serum evidence of inflammation, and the risk for recurrent coronary events in 388 consecutive patients undergoing coronary stent implantation. Patients were grouped according to the median CRP level (0.6 mg/dl) and to the presence of statin therapy.
resultsA primary combined end point event occurred significantly more frequently in patients with elevated CRP levels without statin therapy (RR [relative risk] 2.37, 95% CI [confidence interval] [1.3 to 4.2]). Importantly, in the presence of statin therapy, the RR for recurrent events was significantly reduced in the patients with elevated CRP levels (RR 1.27 [0.7 to 2.1]) to about the same degree as in patients with CRP levels below 0.6 mg/dl and who did not receive statin therapy (RR 1.1 [0.8 to 1.3]).
conclusionsStatin therapy significantly attenuates the increased risk for major adverse cardiac events in patients with elevated CRP levels undergoing coronary stent implantation, suggesting that statin therapy interferes with the detrimental effects of inflammation on accelerated atherosclerotic disease progression following coronary stenting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.